A phase I/II trial evaluating galinpepimut-S in combination with KEYTRUDA in five cancer indications
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Galinpepimut S (Primary) ; Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Ovarian cancer; Small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 04 Jun 2018 According to a SELLAS Life Sciences Group media release, this trial is expected to be initiated in the third quarter of 2018.
- 04 Oct 2017 New trial record
- 02 Oct 2017 This trial is expected to be initiated in 1H 2018, according to a SELLAS Life Sciences Group media release.